1-3 of 3
Annalynn Williams, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients

Anthony R. Mato, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, John N. Allan, MD, Danielle M. Brander, MD, John M. Pagel, MD PhD, Chaitra S. Ujjani, MD, Brian T. Hill, MD PhD, Nicole Lamanna, MD, Frederick Lansigan, MD, Ryan Jacobs, MD, Mazyar Shadman, MD, Alan P Skarbnik, MD, Jeffrey J. Pu, MD PhD, Paul M. Barr, MD, Alison R. Sehgal, MD, Bruce D. Cheson, MD, Clive S Zent, MD, Hande H. Tuncer, MD, Stephen J. Schuster, MD, Peter V. Pickens, MD, Nirav N Shah, MD, Allison M. Winter, MD, Kaitlin Kennard, RN, BSN, Krista Isaac, DO, MS, Colleen Dorsey, BSN, RN, Alexandra Marie Vandegrift, BA, Arun K Singavi, MD, Annalynn Williams, MS, Christina Howlett, PharmD, Hanna Weissbrot, BS, Naveed Ali, MD, Sirin Khajavian, MD, Andrea Sitlinger, MD, Eve Tranchito, BS, Joanna Rhodes, MD, Erica Bharat Bhavsar, BS, Neil Bailey, MS, Bhavisha Patel, MD, Timothy F. Burns, MD, Melissa Yacur, MD, Mansi Malhotra, BS, Sasanka Handunnetti, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Chadi Nabhan, MD MBA, FACP
Journal: Blood
Blood (2017) 130 (Supplement 1): 4315.
https://doi.org/10.1182/blood.V130.Suppl_1.4315.4315
Published: 2017
Journal Articles

Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies

Anthony R. Mato, MD, John N. Allan, MD, John M. Pagel, MD PhD, Danielle M. Brander, MD, Brian T. Hill, MD PhD, Bruce D. Cheson, MD, Richard R. Furman, MD, Nicole Lamanna, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Ryan Jacobs, MD, Frederick Lansigan, MD, Paul M. Barr, MD, Mazyar Shadman, MD, Alan P Skarbnik, MD, Douglas F. Beach, MD, Jeffrey J. Pu, MD PhD, Alison R. Sehgal, MD, Allison M. Winter, MD, Clive S Zent, MD, Hande H. Tuncer, MD, Arun K Singavi, MD, Stephen J. Schuster, MD, Peter V. Pickens, MD, Nirav N Shah, MD, Annalynn Williams, MS, Christina Howlett, PharmD, BCOP, Hanna Weissbrot, BS, Naveed Ali, MD, Bhavisha Patel, MD, Krista Isaac, DO, MS, Joanna Rhodes, MD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Sirin Khajavian, MD, Elizabeth T Chatburn, BS, Andrea Sitlinger, MD, Eve Tranchito, BS, Erica Bharat Bhavsar, BS, Neil Bailey, MS, Timothy F. Burns, MD, Melissa Yacur, MD, Mansi Malhotra, BS, Sasanka Handunnetti, MD, Kaitlin Kennard, RN, BSN, Chadi Nabhan, MD MBA, FACP, Chaitra S. Ujjani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3011.
https://doi.org/10.1182/blood.V130.Suppl_1.3011.3011
Published: 2017
Journal Articles

Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients

Annalynn Williams, MS, Elizabeth Baloga, Andrea Baran, MS, Margaret Helber, PharmD, Jeremiah Moore, PharmD, Carla Casulo, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD, Clive S Zent, MD, Paul M. Barr, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4050.
https://doi.org/10.1182/blood.V130.Suppl_1.4050.4050
Published: 2017